How can anti-nuclear antibody (ANA) positive patients who also have undifferentiated connective tissue disease (UCTD) quickly find a diagnosis? Conventional biomarker tests available today can still leave some patients without the required answers to end their diagnostic journey.
In this webinar, attendees will gain insights into emergent biomarkers for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The speakers will share how novel T Cell biomarkers can offer more confident diagnoses of SLE, particularly when conventional biomarkers are insufficient. Moreover, the attendees will be introduced to a new panel of biomarkers specifically designed to address the diagnostic challenges of seronegative RA, enhancing detection and treatment strategies.
The expert speakers will also share their research into novel biomarkers that can become tools for attendees and help in the confident diagnosis of this challenging patient population.
Register for this webinar today to learn how clinical biomarkers can help expedite diagnoses and optimize treatment strategies for ANA patients with undifferentiated connective tissue disease.
Speakers
Dr. George Muñoz, MD, Rheumatologist and Internist, The Institute for Functional Medicine
George Muñoz, MD, is a board-certified rheumatologist and internist, fellowship trained in rheumatology/immunology at Harvard Medical School affiliates the Brigham and Women’s Hospital and the Beth Israel Hospital in Boston. He completed a second fellowship in integrative medicine at the University of Arizona Center for Integrative Medicine founded by Andrew Weil, MD, and was the first recipient of the Jones/Lovell Rheumatology Scholar Award for 2006-2008. He is a national speaker, lecturer, published author, and co-editor. He serves as chief of integrative medicine and integrative rheumatology for the American Arthritis and Rheumatology Associates (AARA), the largest rheumatology super-group in the US. He is a futurist and innovator, “specializing in the patient journey and experience” as a cornerstone and guiding principal for healthcare stakeholders to emulate and innovate.
Message Presenter
Dr. Andrew Concoff, MD, Rheumatologist and Chief Innovation Officer, Exagen Inc.
Dr. Andrew Concoff brings a tremendous range of experience across the rheumatology ecosystem to his dual roles as Chief Innovation Officer at Exagen Inc., where he focuses on biomarker development in rheumatic diseases, as well as Chief Medical Officer for United Rheumatology, where he designs and implements real-world evidence projects and negotiates value-based contracts on behalf of rheumatologists with health plans. His domain expertise spans the gap from the basic and clinical science of rheumatology and sports medicine to biomarker development and implementation designed to improve patient outcomes and the value of care.
After training as one of the few doctors in the nation to have completed fellowships in both rheumatology and sports medicine, Dr. Concoff received a Career Development Award from the NIH for his research in exercise for knee osteoarthritis. He applied this background in a hybrid, orthopedic and rheumatology private practice for 15 years in Southern California. He also served as a Medical Director at a comprehensive wellness center, including supervising the transition to evidence-driven physical therapy, the development of value-based low back pain assessment and treatment program, as well as the development of tissue- and disease-specific rehabilitation protocols and an objective set of criteria to determine a patient’s candidacy for total joint replacement.
Dr. Concoff has remained active in clinical research and teaching. His published research includes big data and health economic analyses in rheumatic diseases as well as guideline development on behalf of numerous medical societies. Dr. Concoff has also served as a Clinical Reviewer for the Institute for Clinical and Economic Review’s (ICER) cost-effectiveness assessments of both targeted synthetic and biologic medications for rheumatoid arthritis.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Rheumatologists
- Rheumatology Nurse Practitioners
- Rheumatology Physician Assistants
- Generalists
- Immunologists
- Healthcare professionals
What You Will Learn
In this webinar, attendees will gain insights into:
- A greater understanding of emergent biomarkers for SLE and RA
- How novel T Cell biomarkers could be used to confidently clarify the diagnosis of SLE when conventional biomarkers fail
- A new panel of novel biomarkers intended designed to close the seronegative gap for RA
Xtalks Partner
Exagen Inc.
Exagen Inc. is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, Calif., Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account